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Abstract: In 1982, the term “prions” (proteinaceous infectious particles) was coined to specify a new
principle of infection. A misfolded isoform of a cellular protein has been described as the causative
agent of a fatal neurodegenerative disease. At the beginning of prion research scientists assumed
that the infectious agent causing transmissible spongiform encephalopathy (TSE) was a virus, but
some unconventional properties of these pathogens were difficult to bring in line with the prevailing
viral model. The discovery that prions (obviously devoid of any coding nucleic acid) can store
and transmit information similarly to DNA was initially even denoted as being “heretical” but is
nowadays mainly accepted by the scientific community. This review describes, from a historical
point of view, how the “protein-only hypothesis” expands the Central Dogma. Definition of both, the
prion principle and the Central Dogma, have been essential steps to understand information storage
and transfer within and among cells and organisms. Furthermore, the current understanding of the
infectivity of prion-proteins after misfolding is summarized succinctly. Finally, prion-like amyloids
and functional amyloids, as found in yeast and bacteria, will be discussed.
Keywords: prion; Central Dogma; protein misfolding; amyloid; prion-like amyloids;
functional amyloids
1. Introduction
Prions (proteinaceous infectious particles, PrPTSE (TSE = transmissible spongiform
encephalopathy)) are the causative agents of fatal neurodegenerative diseases as bovine spongiform
encephalopathy (BSE) in cattle, scrapie in sheep, chronic wasting disease (CWD) in cervids and
Creutzfeldt-Jakob disease in humans [1,2]. In a process that can occur sporadically, by genetic mutations
or by the uptake of prions, the cellular prion protein (PrPC) is structurally transferred in a misfolded
(then pathogenic) isoform (PrPTSE) [3]. In a self-propagating process, more disease-associated,
transmissible PrPTSE becomes accumulated in the central nervous system causing progressive
spongiform changes [4]. Prions are pathogens that fundamentally differ from bacteria, viruses
or fungi as they are thought to consist essentially of host encoded prion protein lacking a coding
nucleic acid. PrPTSE is characterized by an increased β-sheet content and tends to form highly
ordered amyloid structures [5]. Similarly to prion diseases, neurodegenerative diseases such as
Alzheimer’s disease and Parkinson’s disease are neuropathologically characterized by the aggregation
and deposition of misfolded endogenous proteins in the central nervous system. Albeit proteins
from different neurodegenerative diseases differ in terms of amino acid sequences and native folds,
their disease-associated proteins form extracellular amyloid deposits or intracellular amyloid-like
inclusions. Principally, amyloids need not to be related to diseases but can also be beneficial as in
bacteria (functional amyloids) or yeast (prion-like proteins) where they contribute to cell stability or
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act as inheritable elements [6,7]. Amyloids can be transferred from cell to cell or even from organism
to organism. At least in case of prion diseases, amyloids can transfer disease by the transmission
of specific, structurally altered, isoforms of cellular proteins. The discovery of functional amyloids,
prion-like proteins and prions (including different strains as outlined below) revealed the necessity to
expand the Central Dogma of transcription and subsequent translation being the dominant ways of
information transfer in and between living cells and organisms (Figure 1).
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“elongation-phase” protofilaments are formed by further accumulation of prion proteins to the
PrPTSE-nuclei. Once larger fibrils are formed they tend to break into smaller units during the
“fragmentation phase”. Further cycles of elongation and fragmentation finally result in an exponential
increase of PrPTSE.
PrPTSE does not only spread from cell to cell but also from individual to individual as it naturally
occurs in scrapie and CWD [17–19]. Prions can exist as different strains similarly to bacteria or
viruses. Although sharing the same amino acid sequence, prions from one host can adopt different
conformations. A prion strain is characterized by its specific PrPTSE-conformation, the potential of
infection and by PrPTSE spreading and deposition in the brain and other prion-associated tissues [20].
A high resolution structure for PrPTSE is not available and the conversion process is still not understood
in detail [21,22]. Different strains also occur in Alzheimer’s and Parkinson’s disease-associated
aggregated proteins [23,24]. Similarly to prion diseases, the pathology of these protein misfolding
diseases can vary when different strains are present as the protein conformation has a direct impact on
disease establishment and progression.
Several cofactors, such as polyanions (nucleic acids and proteoglycans) and lipids are discussed
in the literature to be involved in the prion infectivity process [11]. These cofactors obviously play
a fundamental role as catalysts and may stabilize oligomers. Recently, Simoneau et al. published
data that indicate a specific role of short non-coding RNA-molecules in the generation of prions [25].
They showed that originally innocuous recombinant prion protein could be converted to a prion-like
conformation in the presence of small RNA-molecules isolated from prion fibrils.
4. Prion-Like Amyloids and Functional Amyloids in Yeast and Bacteria
The understanding of prion biogenesis has profoundly been increased by the discovery of
prion-like phenomena in yeast. In mammals, amyloids can be associated with a group of devastating
neurodegenerative diseases, but yeast prions do not result in cell death [26,27]. Over the past few years,
the number of yeast prions has rapidly grown [28]. Yeast prions can act as heritable proteinaceous
elements and are propagated epigenetically. In Saccharomyces cerevisiae the normal cellular proteins
Sup35 and URE2 can be converted to the self-propagating amyloids PSI+ and URE3, respectively.
Sup35 acts as a translation termination factor, an ability that becomes impaired upon conversion to
PSI+. URE2 is a nitrogen catabolite repressor once transformed into URE3 allowing growth on poor
nitrogen sources. Other yeast prions are involved in the regulation of transcription, translation and
in the biogenesis of ribosomes [28]. Even though amyloids in yeast do not cause severe disease as in
mammals, they share several features with prions as they are transmissible and continuously replicate
their structure and disseminate their self-replicating activity [29,30]. Not all amyloids are prions,
but several amyloids in yeast act prion-like [31].
In Escherichia coli, the curli-protein, that assembles on the outer cell-membrane, is an example
for functional amyloids [32,33]. Organisms such as E. coli have developed the ability to direct
amyloid formation spatially and temporally. Such functional amyloids fulfill a variety of important
physiological roles and are not toxic to the organism that produces them. Curli is the main protein
component in biofilms of Gram-negative bacteria and stabilizes the biofilm-matrix, is important for
cell-adhesion, cell-cell contact and plays a role in immune response [34]. The curli specific genes
are found in two operons. The major and minor curli subunits, CsgA and CsgB, are encoded by the
csgBAC operon. Once CsgA is secreted across the outer membrane as an unstructured soluble peptide,
it is templated into an amyloid on the cell surface by CsgB [34]. In contrast to mammalian prions and
yeast-amyloids, bacterial amyloids are neither infectious nor transmissible therefore belonging to the
group of functional amyloids.
5. Conclusions
Proteins tend to aggregate under specific conditions. Protein aggregation can occur in vivo and
in vitro, ordered and disordered [31]. Amyloids are insoluble fibrous protein aggregates that are
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examples of ordered aggregates. In contrast, aggregated proteins found in vivo in inclusion bodies are
disordered. Amyloids are highly ordered β-sheet rich protein assemblies that have been found in a
variety of functional or pathogenic contexts. Mammalian prions are characterized by their ability to be
infectious and self-replicating [35]. In humans they are associated with neurodegenerative diseases.
While in yeast similar phenomena have been shown (prion-like amyloids), these proteins do not
cause disease or cell-death [26]. In bacteria functional amyloids have been discovered that do not
act in a prion-like manner [36]. In bacteria the timing, localization and structure of amyloid fibers is
determined by dedicated molecular control systems. Those control systems can be turned on and off
depending on the benefit of the cell under specific environmental conditions. In case of prion diseases,
the onset of protein conversion is sporadic, genetically based or induced by the uptake of a misfolded
prion protein isoform. Once the misfolding process has begun it cannot be stopped and finally leads
to death.
Prion-like amyloids and functional peptides also occur in humans and mammals. While they can
act as inheritable elements in yeast, prion like-amyloids in humans are mainly recognized in the context
of disease (e.g., Alzheimer’s diseases, Parkinson’s disease) [37]. Recently published data provide
evidence for a prion-like transmission of Aβ pathology in Alzheimer’s disease, and for α-synuclein
causing multiple system atrophy in humans with parkinsonism, respectively [38,39]. An example for a
functional amyloid in humans is Pmel17 playing an important role in the biosynthesis of the pigment
melanin [40,41].
Thus, besides DNA and RNA, proteins can transmit information from cell to cell or even from
organism to organism by distinct structural protein foldings (Figure 1). Besides nucleic acids, prions
and prion-like proteins represent additional molecules for information storage and transmission.
Information stored in distinct conformations of prion molecules can convert PrPC into PrpTSE in the
course of infection. This expands the Central Dogma as it demonstrates the possibility of information
transfer from protein to protein. Future research will elucidate whether amyloids (in particular
functional amyloids) are more common in life than it is assumed so far.
Conflicts of Interest: The author declares no conflict of interest.
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